I heard Elon say that if you're a surgeon now, there's just no point. Don't train to be a surgeon. In a couple of years time, Optimus and AI generally are going to be better than any surgeon that's ever lived.Do you think these things are true. >> Well, you know, I I'm pretty sure it was Hinton that famously/ infamously said there will be no need for radiologists anymore. That was 10 years ago, I think, that he said that.He set a deadline that we've already passed. Radiology is doing great as a profession. ...

RadNet FY Conference Summary Company Overview - **Company**: RadNet (NasdaqGM:RDNT) - **Event**: FY Conference held on March 12, 2026 Key Points Current State and Outlook - RadNet experienced a strong performance in 2025, with revenue growth of over **14.8%** and substantial EBITDA growth, marking the best quarter in the company's history [3][6] - The company anticipates revenue growth for 2026 in the range of **17%-19%** and EBITDA growth between **18% and 22%**, indicating expected margin improvement [6] Digital Health Segment - The digital health segment is projected to grow over **50%**, driven by both organic growth and acquisitions, including the recent acquisition of Gleamer [7] - RadNet is focusing on transparency in its digital health initiatives, introducing metrics like annual recurring revenue (ARR) for better tracking [8] Acquisition of Gleamer - The acquisition of Gleamer is significant as it enhances RadNet's AI capabilities in X-ray, which is crucial since X-ray accounts for about **25%** of RadNet's procedure volume [10][12] - Gleamer has shown impressive growth, with an ARR increase of over **90%** since 2022, and RadNet expects to integrate Gleamer's technologies to improve efficiency and reduce costs [13] Revenue Synergies - RadNet estimates **$7 million** in revenue synergies from cross-selling and upselling opportunities through the integration of Gleamer [15] - The company aims to reduce reliance on RadNet as a customer for its digital health segment from **45%** in 2025 to **33%** in 2026, with a target of below **20%** by the end of 2028 [17][18] Labor Efficiency and Cost Management - Labor costs have been a significant challenge, with a **4%-5%** increase in labor costs built into the 2026 guidance [24] - Technologies like TechLive and C-mode are being implemented to improve labor efficiency, with TechLive allowing remote MRI scanning to reduce exam room closures [25][26] Industry Trends - Advanced imaging is a key growth area, currently comprising about **28.6%** of procedure volume but driving over **60%** of revenue [29] - The company is well-positioned to capture more advanced imaging as technology evolves, with expectations for continued growth in this segment [30][31] Economic Environment - RadNet has not observed any significant changes in demand or procedure volume despite broader economic concerns, indicating resilience in its operations [33] - The company benefits from favorable Medicare pricing and strong rate increases from capitated and commercial payers, recognizing the value of outpatient services compared to hospital pricing [34][35] Strategic Positioning - RadNet's strong regional presence allows it to negotiate effectively with payers, as it comprises a significant part of the outpatient imaging market in its operational areas [34][36] Conclusion - RadNet is positioned for robust growth in 2026, driven by strategic acquisitions, a focus on digital health, and advancements in imaging technology, while effectively managing labor costs and maintaining strong relationships with payers.

Summary of the Conference Call on RadNet's Acquisition of Gleamer Industry and Company Overview - **Industry**: Radiology and AI-powered health informatics - **Companies Involved**: - RadNet: The largest outpatient imaging chain in the U.S. with over 425 imaging centers and partnerships with 26 hospital chains [3][4] - DeepHealth: A leader in AI-powered health informatics, now integrating Gleamer into its operations [9][10] - Gleamer: A rapidly growing startup specializing in AI solutions for radiology, with over 90% year-over-year growth in annual recurring revenue (ARR) [14] Core Points and Arguments - **Strategic Acquisition**: RadNet's acquisition of Gleamer aims to enhance routine imaging services and leverage AI to improve patient care and operational efficiency [1][8][18] - **Market Position**: The combined entity will serve over 2,700 customer contracts globally, with a projected revenue of $135 million to $145 million and ARR of $120 million to $140 million by 2026, indicating significant growth potential [20][21] - **AI Integration**: The acquisition will accelerate the development of automated diagnostics, improving workflow efficiency and clinical outcomes by addressing workforce shortages and enhancing diagnostic accuracy [19][44] - **Product Synergies**: The integration will combine complementary products and clearances, allowing for a broader market reach and enhanced product offerings [22][23] Additional Important Insights - **Operational Efficiency**: The acquisition is expected to drive operational efficiencies across RadNet's workflows, addressing labor shortages and improving clinical outcomes [18][34] - **Innovative Solutions**: The combined portfolio will cover over 75 indications across multiple specialties, enhancing the ability to detect diseases earlier and optimize diagnostic processes [32][33] - **Focus on Customer Experience**: The priority post-acquisition is to ensure a seamless transition for customers, maintaining service continuity while integrating the best features of both companies [40][41] - **Ecosystem Approach**: The companies view their competition as being against diseases rather than other firms, emphasizing collaboration within the broader AI ecosystem [55][59] Conclusion The acquisition of Gleamer by RadNet represents a transformative step in the radiology industry, combining extensive resources and expertise to enhance patient care through innovative AI solutions and improved operational efficiencies. The strategic alignment of both companies positions them as leaders in the market, with a strong focus on automated diagnostics and customer satisfaction.

Financial Data and Key Metrics Changes - Total company revenue increased by 14.8% to $547.7 million, while Adjusted EBITDA rose by 16.9% to $87.7 million compared to the previous year's fourth quarter [8][18] - Digital Health segment revenue grew by 48.2% to $27.9 million, with Adjusted EBITDA increasing by 8.9% to $4.9 million [8][18] - Adjusted earnings per share for RadNet was flat at $0.23 per share compared to $0.04 per share in the last year's fourth quarter [19] Business Line Data and Key Metrics Changes - Imaging center revenue was driven by a 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth [9] - Advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from the previous year [9] - The Digital Health segment's revenue for the full year reached $92.7 million, exceeding original guidance [20] Market Data and Key Metrics Changes - The company opened seven de novo facilities in 2025 to address backlogs and access points for identified patient populations [10] - 151 of RadNet's 418 centers, or 36.1%, are held within health system partnerships, which have been instrumental in increasing procedural volume [11] Company Strategy and Development Direction - The acquisition of Gleamer is expected to enhance RadNet's Digital Health capabilities and position it as the largest provider of radiology clinical AI solutions worldwide [27][36] - The company aims to leverage AI to improve efficiency, productivity, and accuracy in imaging workflows, addressing labor shortages in the industry [26][29] - Future growth is anticipated to come from expanding joint ventures and acquisitions, particularly in new markets [10][76] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting or exceeding 2025 guidance levels due to strong performance in the fourth quarter [19] - The company anticipates 17%-19% imaging center revenue growth for 2026, driven by same-center performance and new acquisitions [22] - Management highlighted the importance of AI in enhancing productivity and addressing workforce challenges in radiology [45][47] Other Important Information - At year-end 2025, RadNet's cash balance was $776 million, with a net debt to Adjusted EBITDA leverage ratio of approximately 1.0x [13] - The company introduced a new metric, Annual Recurring Revenue (ARR), for the Digital Health segment, which was $75.4 million at the end of 2025 [24] Q&A Session Summary Question: How does RadNet view AI's impact on radiology? - Management believes AI will enhance productivity and accuracy rather than disrupt the workforce, addressing critical needs in radiology [44][45] Question: Can you provide context on the ARR growth? - ARR is expected to grow significantly due to contributions from Gleamer and other acquisitions, with a target of approximately $140 million by the end of 2026 [56][87] Question: What efficiency gains are expected from the Gleamer acquisition? - The integration of Gleamer's AI capabilities is anticipated to improve operational efficiency, particularly in routine imaging areas like X-ray [70][72] Question: Are there more opportunities for joint ventures with hospital systems? - There has been a notable increase in inquiries from hospital systems seeking partnerships, driven by staffing shortages [71][76] Question: What is the expected impact of weather conditions on EBITDA guidance? - Management indicated that labor increases and adverse weather conditions are embedded in the EBITDA guidance for 2026 [93][94]

Financial Data and Key Metrics Changes - Total company revenue increased by 14.8% to $547.7 million, while Adjusted EBITDA rose by 16.9% to $87.7 million compared to the same quarter last year [6][17]. - Digital Health revenue surged by 48.2% to $27.9 million, with Adjusted EBITDA increasing by 8.9% to $4.9 million from the previous year's fourth quarter [6][17]. - Adjusted earnings per share for RadNet remained flat at $0.23 per share compared to $0.04 per share in the last year's fourth quarter [18]. Business Line Data and Key Metrics Changes - Imaging center revenue growth was driven by a 14.1% aggregate and 9.6% same-center advanced imaging procedural volume growth in the fourth quarter [6][7]. - Advanced imaging represented 28.6% of RadNet's procedural volume, an increase of 178 basis points from the same quarter last year [8][9]. Market Data and Key Metrics Changes - The demand for diagnostic imaging continues to rise, benefiting from the shift of procedural volumes from hospitals to ambulatory freestanding centers [6][10]. - RadNet's health system partnerships have increased procedural volume through physician relationships, with 36.1% of RadNet's centers held within health system partnerships [10]. Company Strategy and Development Direction - The company plans to continue expanding its digital health portfolio, focusing on AI-powered solutions to enhance workflow and clinical capabilities in radiology [11][12]. - The acquisition of Gleamer is expected to strengthen RadNet's position in the radiology AI market, enhancing operational efficiency and expanding its global footprint [26][34]. - The company anticipates significant growth in both imaging center revenue and digital health revenue, with guidance for 2026 indicating 17%-19% growth in imaging center revenue and 45%-55% growth in digital health revenue [21][22]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to grow despite challenges in the labor market and increasing operational demands [42][45]. - The integration of AI solutions is seen as a critical need to address workforce shortages and improve productivity and accuracy in radiology [42][44]. - The company expects to achieve a strong cash and liquidity position, with a cash balance of $776 million and a net debt to Adjusted EBITDA leverage ratio of approximately 1.0 at year-end 2025 [12][20]. Other Important Information - The company opened seven new facilities in 2025 and plans to continue expanding through acquisitions and joint ventures [9][10]. - The introduction of a new metric, Annual Recurring Revenue (ARR), aims to provide better transparency into the growth of the Digital Health division, with an expected ARR of $140 million by the end of 2026 [22][23]. Q&A Session Summary Question: How does RadNet view the impact of AI on radiology? - Management believes AI will enhance productivity and accuracy rather than disrupt the workforce, addressing critical needs in radiology due to labor shortages [42][44]. Question: Can you provide context on the growth of ARR and its contributors? - The ARR is expected to grow significantly due to contributions from Gleamer and the annualization of the iCAD acquisition, alongside other product and service growth [55][56]. Question: What efficiencies are expected from the Gleamer acquisition? - The integration of Gleamer's AI capabilities is anticipated to improve operational efficiency, particularly in routine imaging areas like X-ray, allowing radiologists to focus on more complex cases [60][67]. Question: Are there increasing opportunities for joint ventures with hospital systems? - There has been a notable increase in inquiries from hospital systems seeking partnerships, driven by staffing shortages and the need for comprehensive radiology solutions [70][72]. Question: What is the expected impact of weather conditions on EBITDA guidance? - Management indicated that labor increases and adverse weather conditions are embedded in the EBITDA guidance for 2026, with anticipated labor cost increases of over $30 million [91][92].

Core Viewpoint - Mirion Technologies reported strong financial results for the fourth quarter and full year 2025, with significant order growth and provided optimistic guidance for 2026, reflecting robust market fundamentals and strategic acquisitions [1][2]. Financial Results - For the fiscal year ended December 31, 2025, total revenues reached $925.4 million, up from $860.8 million in 2024, marking a year-over-year increase of approximately 7.0% [3]. - The company reported a net income of $29.8 million for 2025, compared to a net loss of $36.6 million in 2024 [3]. - Adjusted EBITDA for 2025 was approximately $227.9 million, an increase from $203.6 million in 2024, reflecting a margin of about 24.6% [5]. 2026 Guidance - Mirion anticipates adjusted earnings per share (EPS) to be between $0.50 and $0.57, including stock-based compensation [1]. - The company expects adjusted free cash flow to range from $155 million to $175 million, with an adjusted free cash flow conversion rate of approximately 54% to 58% of adjusted EBITDA [1]. - Organic revenue growth is projected to be between 5.0% and 7.0%, while total revenue growth is expected to be between 22.0% and 24.0% [1]. Order Growth and Market Position - In 2025, Mirion booked over $1 billion in orders, including approximately $150 million from a large opportunity pipeline, indicating strong demand across all three Nuclear Power verticals [1][2]. - The company highlighted its expanding nuclear power portfolio and strategic acquisitions, such as Paragon Energy Solutions, as key drivers for future growth [1][2]. Balance Sheet Highlights - As of December 31, 2025, total assets amounted to $3,588.1 million, up from $2,636.0 million in 2024, with significant increases in cash and cash equivalents [3]. - Total liabilities were reported at $1,671.2 million, compared to $1,076.9 million in the previous year, reflecting the impact of acquisitions and operational growth [3]. Cash Flow Analysis - Net cash provided by operating activities for 2025 was $143.3 million, an increase from $99.1 million in 2024 [4]. - The company reported a net cash used in investing activities of $694.6 million, primarily due to acquisitions [4].

Core Points - Hyperfine, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4th at 8:10 AM ET [1][12] - The company is known for its Swoop® system, the first FDA-cleared AI-powered portable MRI for brain imaging [1][4] Company Overview - Hyperfine, Inc. is a health technology company focused on revolutionizing brain imaging with its portable, ultra-low-field MRI system [4] - The Swoop® system is designed for brain imaging across all ages and provides clinically relevant diagnostic imaging [3][4] - Founded by Dr. Jonathan Rothberg, the company aims to make diagnostic imaging more accessible globally [4] Upcoming Events - A live audio webcast of the conference presentation will be available on Hyperfine's investor page [2] - Management will also conduct in-person meetings during the conference [2]

Core Insights - GE HealthCare has announced the acquisition of Intelerad for $2.3 billion in cash, emphasizing its commitment to cloud-enabled and AI-powered healthcare solutions [1][5][6] - The acquisition aims to triple GE HealthCare's cloud-enabled product offerings by 2028, enhancing its capabilities in both inpatient and outpatient care settings [1][2][6] Company Overview - Intelerad is a prominent provider of medical imaging software and digital workflow solutions, particularly in outpatient care, which complements GE HealthCare's hospital-based imaging leadership [2][12] - The combined capabilities of GE HealthCare and Intelerad will create a comprehensive, cloud-first imaging solution that spans various care settings, including academic medical centers and ambulatory networks [2][6] Strategic Fit and Benefits - The acquisition is expected to accelerate GE HealthCare's digital transformation by creating a fully connected imaging ecosystem that includes outpatient, teleradiology, and hospital settings [5][6] - It will enhance GE HealthCare's portfolio with AI and workflow orchestration capabilities, contributing to a SaaS business model that is anticipated to generate high recurring revenues [5][6][8] Financial Projections - GE HealthCare estimates that Intelerad will generate approximately $270 million in revenue in its first full year, with around 90% of this being recurring revenue and an EBITDA margin exceeding 30% [8] - The transaction is expected to be immediately accretive to top-line growth and Adjusted EBIT margin, although it may be slightly dilutive to Adjusted EPS in the short term due to financing costs [8][9] Market Opportunity - The acquisition allows GE HealthCare to tap into a $2 billion-plus growth segment in outpatient enterprise imaging, with cloud-based solutions projected to grow at a double-digit rate in the medium term [7][8] - The demand for integrated solutions that enhance operational efficiencies is driving this growth, aligning with the broader trend of shifting procedures to outpatient settings [7][8]

Core Insights - DeepHealth's Operations Suite™ has been selected by Wichita Radiological Group (WRG) to modernize its operations and enhance patient-centered care coordination across its multi-site network [1][2][3] Company Overview - DeepHealth is a wholly owned subsidiary of RadNet, Inc. and specializes in AI-powered health informatics aimed at improving operational efficiency and clinical outcomes in imaging [7] - RadNet, Inc. is a leading provider of diagnostic imaging services in the U.S., operating 407 outpatient imaging centers and employing approximately 11,000 team members [6] Product Features - The Operations Suite™ offers a modular suite of AI-powered applications designed to streamline operational workflows, enhance productivity, and improve staff experience through task automation and data interoperability [2][4] - Key capabilities of the Operations Suite™ include workflow automation for patient intake and scheduling, integration of data across systems, and role-specific experiences to optimize resource utilization [4][10] Strategic Goals - The five-year agreement between DeepHealth and WRG aims to improve efficiency, boost collaboration, and strengthen care coordination within the imaging practice [2][4] - The Operations Suite™ is expected to transform operational workflows from scheduling to billing, ensuring a more personalized and transparent patient experience [3][4] Market Position - The selection of DeepHealth's Operations Suite™ by WRG reflects a trend among forward-thinking practices preparing for the future of imaging through modernization and AI integration [4] - DeepHealth is positioned as a trusted partner in the radiology sector, focusing on reducing administrative burdens and enhancing care delivery [4][7]

Core Insights - The Agfa-Gevaert Group reported stable adjusted EBITDA in Q1 2025 compared to Q1 2024, with improved sales mix and effective cost control offsetting declines in traditional film markets [1][5][10]. Financial Performance - Total revenue decreased by 3.2% from €250 million in Q1 2024 to €242 million in Q1 2025 [4][10]. - Adjusted EBITDA remained stable at €2 million, representing 0.9% of revenue, up from 0.7% in Q1 2024 [4][10]. - The net loss for the period was €20 million, slightly improved from a loss of €21 million in Q1 2024 [4][10]. Division Performance HealthCare IT - Revenue increased by 12.0% to €57 million, with adjusted EBITDA rising from €1.3 million to €5.0 million [2][9]. - The division saw a 63% increase in rolling order intake over 12 months, with a significant share from new customers and cloud-related contracts [11]. - Gross profit margin improved from 43.8% to 47.9% [11]. Digital Print & Chemicals - Revenue grew by 5.8% to €97 million, with adjusted EBITDA increasing from €1.0 million to €2.3 million [13][17]. - Ink sales rose by 16%, although equipment sales were affected by a weaker investment climate [17]. Radiology Solutions - Revenue declined by 15.6% to €73 million, with adjusted EBITDA dropping to -€4.5 million [15][16]. - The division faced challenges due to a significant decline in medical film markets, particularly in China [5][10]. Contractor Operations - Revenue decreased by 29.1% to €15 million, with adjusted EBITDA down by 30.6% [18]. Outlook - The company expects continued strong performance from growth engines in 2025, with a stronger second half anticipated due to seasonal factors [8][10]. - Cost optimization measures for traditional film activities are expected to yield initial savings in the second half of 2025 [1][5].